Buy NowMedium
NMRA is basing in an early Stage 1 consolidation with price forming higher highs and higher lows above the short-term EMAs, signaling stabilization and a foundation for a trend reversal. Short-term EMAs (9/21) have shifted to support and price is holding above them, offering a favorable pullback entry. The active Higher Highs & Higher Lows pattern indicates demand dominance and a bullish medium-term stance, despite the long-term downtrend persisting.
- ↑Seven clinical programs including NMRA 511 and Nevacopran address major unmet neurotherapeutic needs.
- ↑COSTAL 1 top-line data due by year-end 2025, a key valuation catalyst.
- ↓Q1 2025 net loss widened to $68 M; Q3 2024 opex at $76.6 M intensifies cash burn.
Full analysis →